Navegar

Colección

Datos Estadísticas

Artículo

Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Registro:

Documento: Artículo
Título:Pharmacokinetics interaction studies between rifampicin and protease inhibitors: Methodological problems
Autor:Toibaro, J.J.; Losso, M.H.
Filiación:Hospital José María Ramos Mejía, Pabellón de Clínica, Buenos Aires, Argentina
Hospital General de Agudos José Maria Ramos Mejía, Urquiza 609, Pabellón de Clínica, 20 Piso, C1221 ADC Buenos Aires, Argentina
Palabras clave:aminotransferase; cytochrome P450 3A4; glycoprotein P; lopinavir plus ritonavir; proteinase inhibitor; rifampicin; ritonavir; ritonavir plus saquinavir; saquinavir; unclassified drug; aminotransferase blood level; clinical trial; drug absorption; drug excretion; drug metabolism; highly active antiretroviral therapy; human; Human immunodeficiency virus infection; letter; liver toxicity; mixed infection; patient compliance; pharmacokinetics; priority journal; side effect; tuberculosis; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Drug Interactions; HIV Protease Inhibitors; Humans; Liver Diseases; Research Design; Rifampin; Tuberculosis
Año:2008
Volumen:22
Número:15
Página de inicio:2046
Página de fin:2047
DOI: http://dx.doi.org/10.1097/QAD.0b013e3283112bb7
Título revista:AIDS
Título revista abreviado:AIDS
ISSN:02699370
CODEN:AIDSE
CAS:aminotransferase, 9031-66-7; cytochrome P450 3A4, 329736-03-0; proteinase inhibitor, 37205-61-1; rifampicin, 13292-46-1; ritonavir, 155213-67-5; saquinavir, 127779-20-8, 149845-06-7; Antibiotics, Antitubercular; HIV Protease Inhibitors; Rifampin, 13292-46-1
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_02699370_v22_n15_p2046_Toibaro

Referencias:

  • Maher, D., Floyd, K., Raviglione, M., (2002) A strategic framework to decrease the burden of TB/HIV, , Geneva, Switzerland: World Health Organization;, WHO/CDSATB/2002.296
  • Piscitelli, S.C., Gallicano, K.D., Interactions among drugs for HIV and opportunistic infections (2001) N Engl J Med, 344, pp. 984-996
  • Dean, G.L., Edwards, S.G., Ives, N.J., Matthews, G., Fox, E.F., Navaratne, L., Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy (2002) AIDS, 16, pp. 75-83
  • Dear Healthcare Provider letter. Roche Pharmaceuticals; 7 February 2005. http://www.fda.gov/medwatch/SAFETY/2005/safe-ty05.htm#lnvirase. [Accessed 11 February 2005]; Nijland, H.M.J., L'homme, R.F.A., Rongen, G.A., van Uden, P., van Crevel, R., Boeree, M.J., High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets (2008) AIDS, 22, pp. 931-935
  • la Porte, C.J.L., Colbers, E.P.H., Bertz, R., Voncken, D.S., Wikstrom, K., Boeree, M.J., Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers (2004) Antimicrob Agents Chemother, 48, pp. 1553-1560
  • Ribera, E., Azuaje, C., Lopez, R.M., Domingo, P., Curran, A., Feijoo, M., Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis (2007) J Antimicrob Chemother, 59, pp. 690-697
  • Gurumurthy, P., Ramachandran, G., Hemanth Kumar, A.K., Rajasekaran, S., Padmapriyadarsini, C., Swaminathan, S., Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease (2004) Antimicrob Agents Chemother, 48, pp. 4473-4475
  • Losso, M.H., Lourtau, L.D., Toibaro, J.J., Saenz, C., Gonzalez, C., The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin (2004) Antivir Ther, 9, pp. 1031-1033

Citas:

---------- APA ----------
Toibaro, J.J. & Losso, M.H. (2008) . Pharmacokinetics interaction studies between rifampicin and protease inhibitors: Methodological problems. AIDS, 22(15), 2046-2047.
http://dx.doi.org/10.1097/QAD.0b013e3283112bb7
---------- CHICAGO ----------
Toibaro, J.J., Losso, M.H. "Pharmacokinetics interaction studies between rifampicin and protease inhibitors: Methodological problems" . AIDS 22, no. 15 (2008) : 2046-2047.
http://dx.doi.org/10.1097/QAD.0b013e3283112bb7
---------- MLA ----------
Toibaro, J.J., Losso, M.H. "Pharmacokinetics interaction studies between rifampicin and protease inhibitors: Methodological problems" . AIDS, vol. 22, no. 15, 2008, pp. 2046-2047.
http://dx.doi.org/10.1097/QAD.0b013e3283112bb7
---------- VANCOUVER ----------
Toibaro, J.J., Losso, M.H. Pharmacokinetics interaction studies between rifampicin and protease inhibitors: Methodological problems. AIDS. 2008;22(15):2046-2047.
http://dx.doi.org/10.1097/QAD.0b013e3283112bb7